ReadCoor
Cambridge
About ReadCoor
ReadCoor is a technology company offering the first true spatial multi-omic platform to the global audience of researchers, clinicians, pharma and diagnostics companies to expand understanding of human biology and to facilitate the creation of new therapeutics for patients. The company’s RC2 Platform simultaneously detects and reads the sequences of tens to thousands of RNA, DNA, proteins, and therapeutics and visualizes sub-cellular nanoscale 3D resolution in every cell throughout any tissue section. The Platform, based on ReadCoor’s proprietary Fluorescent in situ Sequencing (FISSEQ) technology, combines the massive multiplexity of next-generation sequencing (NGS) and high-resolution tissue imaging.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $52.5M
- Funding stage: M&A
- Last round: Series B (Jan 2020)
- Website: readcoor.com
- Phone: (617)453-2660
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/readcoor-72720 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.